July 05, 2012
Press Release No. 1
Clarification by Hitachi Home and Life
Solutions (India) Limited
Substantial
increase in trading volumes have been observed in Hitachi Home and Life
Solutions (India) Limited.
The
Exchange, in order to ensure that investors have latest relevant information
about the company and to inform the market place so that the interest of the
investors is safeguarded, had written to the company.
Hitachi Home and
Life Solutions (India) Limited has vide its letter inter-alia stated, “We would
like to convey that there is no information/announcement pending which can lead
to increase in price/ volume of scrip of the Company
Press Release No. 2
Clarification by Ankur Drugs and Pharma
Limited
Significant
price movement has been observed in Ankur Drugs And Pharma Limited.
The
Exchange, in order to ensure that investors have latest relevant information
about the company and to inform the market place so that the interest of the
investors is safeguarded, had written to the company.
Ankur
Drugs And Pharma Limited has vide its letter inter-alia stated, “The Company
does not have any price sensitive information to disclose under Clause 36 of
the listing agreement".
Press Release No. 3
NSE completes 3090th
Normal Settlement
The
Exchange has successfully completed its 3090th Normal Settlement (Rolling T+2 following SEBI
directive) since inception i.e., Settlement Number N – 2012126 on July 05,
2012. The settlement statistics are as follows:
Particulars |
|
|
N-2012126 |
Total traded quantity (lakhs) |
7476.93 |
Total traded value (Rs. In Crores) |
10341.25 |
Total value of the settlement (Securities) (Rs. In
Crores) |
3165.67 |
Total value of the settlement (Funds) (Rs. In
Crores) |
1133.14 |
Shortages for the settlement |
0.13% |
% of Delivery
( No. of shares deliverable / No. of shares traded ) |
27.07% |
Retail Debt Market has completed its 2363th settlement,
details of which are as follows:
Settlement No. |
Traded Value (Rs.) |
Settlement Value (Rs.) |
|
|
|
Securities |
Funds |
D- 2012126 |
NIL |
NIL |
NIL |